| First Author | Zhou Y | Year | 2018 |
| Journal | Biochim Biophys Acta | Volume | 1864 |
| Issue | 3 | Pages | 860-870 |
| PubMed ID | 29277328 | Mgi Jnum | J:260696 |
| Mgi Id | MGI:6149427 | Doi | 10.1016/j.bbadis.2017.12.028 |
| Citation | Zhou Y, et al. (2018) Induction of cytochrome P450 4A14 contributes to angiotensin II-induced renal fibrosis in mice. Biochim Biophys Acta 1864(3):860-870 |
| abstractText | Angiotensin II (AngII) plays an important role in the pathogenesis of hypertension and associated renal injuries. To elucidate the molecular mechanism by which AngII induces renal damage, we found that AngII infusion significantly induced CYP4A14 expression in renal proximal tubule cells (RPTCs) with marked increases in blood pressure and proteinuria. Renal production of the major CYP4A metabolite, 20-HETE, was also significantly increased in the AngII-treated mice. Compared to wild-type (WT) mice, CYP4A14 knockout (CYP4A14(-/-)) mice exhibited significantly lower levels of blood pressure, renal 20-HETE production, proteinuria and renal fibrosis following AngII infusion. Furthermore, AngII-induced renal expression of profibrotic genes and proinflammatory genes was significantly attenuated in CYP4A14(-/-) mice. In vitro studies using cultured RPTCs demonstrated that AngII significantly induced CYP4A14 expression and 20-HETE production via the MAPK signaling pathway. AngII treatment increased TGF-beta and collagen expression, which was attenuated by the CYP4A inhibitor, TS-011. Moreover, 20-HETE treatment potently induced CYP4A14 expression and TGF-beta and collagen levels. Collectively, these findings suggest that attenuated renal fibrosis in AngII-treated CYP4A14(-/-) mice may result from both reduced systemic blood pressure and renal 20-HETE production. Therefore, CYP4A14 may represent a useful target for the treatment of AngII-associated renal damage. |
